Show simple item record

dc.contributor.authorBošnjak, Berislav
dc.contributor.authorOdak, Ivan
dc.contributor.authorRitter, Christiane
dc.contributor.authorStahl, Klaus
dc.contributor.authorGraalmann, Theresa
dc.contributor.authorSteinbrück, Lars
dc.contributor.authorBlasczyk, Rainer
dc.contributor.authorFalk, Christine S
dc.contributor.authorSchulz, Thomas F
dc.contributor.authorWedemeyer, Hans Heinrich
dc.contributor.authorCornberg, Markus
dc.contributor.authorGanser, Arnold
dc.contributor.authorFörster, Reinhold
dc.contributor.authorKoenecke, Christian
dc.date.accessioned2021-11-15T15:11:21Z
dc.date.available2021-11-15T15:11:21Z
dc.date.issued2021-08-12
dc.identifier.citationFront Immunol. 2021 Aug 12;12:721738. doi: 10.3389/fimmu.2021.721738.en_US
dc.identifier.pmid34456929
dc.identifier.doi10.3389/fimmu.2021.721738
dc.identifier.urihttp://hdl.handle.net/10033/623096
dc.description.abstractHere, we described the case of a B cell-deficient patient after CD19 CAR-T cell therapy for refractory B cell Non-Hodgkin Lymphoma with protracted coronavirus disease 2019 (COVID-19). For weeks, this patient only inefficiently contained the virus while convalescent plasma transfusion correlated with virus clearance. Interestingly, following convalescent plasma therapy natural killer cells matured and virus-specific T cells expanded, presumably allowing virus clearance and recovery from the disease. Our findings, thus, suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections. If confirmed in larger clinical studies, these data could be of general importance for the treatment of COVID-19 patients.en_US
dc.language.isoenen_US
dc.publisherFrontiersen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCD19 CAR-T cellen_US
dc.subjectCOVID – 19en_US
dc.subjectNK cellen_US
dc.subjectSARS – CoV – 2en_US
dc.subjectT cellen_US
dc.subjectconvalescent plasma (CP)en_US
dc.titleCase Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.en_US
dc.typeArticleen_US
dc.identifier.eissn1664-3224
dc.contributor.departmentCiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.en_US
dc.identifier.journalFrontiers in immunologyen_US
dc.source.volume12
dc.source.beginpage721738
dc.source.endpage
refterms.dateFOA2021-11-15T15:11:22Z
dc.source.journaltitleFrontiers in immunology
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
Bosnjak et al.pdf
Size:
945.0Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International